Medicine and Dentistry
Abdominal Fibromatosis
16%
Adjuvant Chemotherapy
16%
Aggressive Fibromatosis
16%
ALK Inhibitor
16%
All Cause Mortality
16%
Arm
16%
Beta 1 Adrenergic Receptor Blocking Agent
16%
Cardiotoxicity
25%
Chemoradiotherapy
16%
Connective Tissue Cancer
20%
Diabetes Mellitus
16%
Diastolic Function
16%
Disease Free Survival
17%
Diseases
42%
Doxorubicin
16%
Embolization
16%
Excision Repair Cross-Complementing
16%
Familial Adenomatous Polyposis
16%
Genetic Background
16%
Immune Checkpoint Inhibitor
81%
Immunotherapy
19%
Ipilimumab
16%
Krukenberg Tumor
16%
Lung Cancer
45%
Lymph Node
16%
Malignant Neoplasm
71%
Medical Cannabis
16%
Medical Record
19%
Metastatic Colorectal Cancer
16%
Microsphere
16%
Multivariate Analysis
20%
Myocarditis
18%
Neoadjuvant Therapy
25%
Neoplasm
48%
Neutropenia
16%
Nivolumab
50%
Non Small Cell Lung Cancer
100%
Oncology
24%
Overall Survival
83%
Oxaliplatin
16%
Paclitaxel
16%
Pembrolizumab
38%
Postoperative Complication
16%
Progression Free Survival
45%
Prospective Study
16%
Rectum Cancer
16%
Retroperitoneal Sarcoma
33%
Retrospective Study
38%
Systolic Dysfunction
16%
Trabectedin
16%
Keyphrases
Adenomatous Polyposis Coli
16%
All-cause Mortality
25%
Cancer Patients
20%
Cancer Therapeutics-related Cardiac Dysfunction
33%
Cardio-oncology
21%
Cardiotoxicity
25%
Chemotherapy
26%
Clinical Outcomes
22%
Confidence Interval
43%
Diastolic Function
16%
Doxorubicin
16%
Early Markers
16%
Familial Adenomatous Polyposis
16%
Genetic Polymorphism
16%
Immune Checkpoint Inhibitors
93%
Inflammatory Markers
16%
Intra-arterial
16%
Ipilimumab
16%
Kaposi Sarcoma
16%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
17%
Lung Cancer
25%
Lymph Node Ratio
16%
Median Overall Survival
21%
Medical Records
22%
Metastatic Non-small Cell Lung Cancer
17%
Microsphere Embolization
16%
Multivariate Analysis
21%
Myocarditis
21%
Neoadjuvant Chemoradiotherapy (nCRT)
16%
Neoadjuvant Therapy
25%
Neutropenia
16%
Neutrophil-to-lymphocyte Ratio
16%
Nivolumab
50%
Non-small Cell Lung Cancer (NSCLC)
79%
Non-small Cell Lung Cancer Patients
19%
Overall Survival
53%
Paclitaxel
16%
Pathological Complete Response
20%
Pembrolizumab
45%
Potential Biomarkers
16%
Predictive Value
16%
Previously Treated
16%
Prognostic Value
19%
Progression-free Survival
28%
Real-life Data
19%
Retroperitoneal Sarcoma
33%
Sarcoma
20%
Systolic Dysfunction
16%
Trabectedin
16%
Type 1 Diabetes Mellitus (T1DM)
16%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
All Cause Mortality
26%
Anaplastic Lymphoma Kinase Inhibitor
16%
Beta 1 Adrenergic Receptor Blocking Agent
16%
Cannabis
16%
Carboplatin
16%
Carcinoma
6%
Cardiotoxicity
8%
Cardiovascular Mortality
5%
Chemoradiation Therapy
16%
Chemotherapy
37%
Chemotherapy Agent
8%
Congestive Heart Failure
6%
COVID-19 Vaccine
16%
Disease Exacerbation
6%
Diseases
17%
Dosimetry
8%
Doxorubicin
16%
Fibromatosis
16%
Heart Injury
7%
Immune Checkpoint Inhibitor
73%
Leiomyosarcoma
8%
Liposarcoma
8%
Major Adverse Cardiac Event
16%
Malignant Neoplasm
58%
Medical Cannabis
16%
Microsphere
16%
Myocarditis
5%
Neoplasm
33%
Neutropenia
16%
Nivolumab
16%
Non Small Cell Lung Cancer
66%
Ovary Carcinoma
16%
Overall Survival
56%
Paclitaxel
16%
Pembrolizumab
30%
Postoperative Complication
16%
Prevalence
8%
Progression Free Survival
22%
Prospective Study
16%
Rectum Cancer
16%
Retroperitoneal Sarcoma
16%
Retrospective Study
35%
Side Effect
10%
Skin Manifestation
16%
Soft Tissue Sarcoma
16%
Systolic Dysfunction
16%
Trabectedin
16%
Troponin
16%
